CalciMedica(CALC) - 2025 Q4 - Annual Results

Exhibit 99.1 CalciMedica Reports 2025 Financial Results and Provides Clinical Updates Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™ Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026 "First and foremost, in acute kidney injury, we and our external advisors have reviewed the unblinded KOURAGE data and have found no evidence of a drug-related toxicity ...